版本:
中国

BRIEF-FDA approves Genentech's cancer immunotherapy Tecentriq

Oct 19 Roche Holding AG :

* FDA approves Genentech's cancer immunotherapy Tecentriq (atezolizumab) for people with a specific type of metastatic lung cancer

* Genentech- FDA approved Tecentriq for treatment of metastatic NSCLC who have disease progression during or following platinum-containing chemo Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐